BDX · News · 20260805N
Licensing / Collaboration Deals
BECTON DICKINSON & CO · 2026-08-05 · Importance 31 · Surprise 42 · In source text
BD partnered with EMS to launch a semaglutide therapy in Brazil using BD’s Vystra injection pen. The initiative expands BD’s drug-delivery-device presence in Brazil and links its pen technology to the country’s GLP-1 treatment market. The reporting did not disclose the partnership’s revenue contribution, investment amount, or launch timetable beyond describing it as a recent partnership.
Key facts
- BD announced a partnership with EMS to launch a semaglutide therapy in Brazil using its Vystra injection pen. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | BD announced a partnership with EMS to launch a semaglutide therapy in Brazil using its Vystra injection pen. |